Document is current
Any future updates will be listed below
-
Authors
Antonazzo, Ippazio Cosimo https://orcid.org/0000-0001-8046-4574
Girolomoni, Giampiero
Patruno, Cataldo
Langella, Roberto
Ottobrino, Veronica
Mantovani, Lorenzo Giovanni
Cortesi, Paolo Angelo
-
Funding
Funding for this research was provided by:
The study was supported by Almirall S.p.A., Milan, Italy. The rapid service fee was also funded by Almirall S.p.A., Milan, Italy
- License Information
-
More Information
Article History
Received: 29 April 2025
Accepted: 16 June 2025
First Online: 9 July 2025
Declarations
:
: Ippazio Cosimo Antonazzo and Roberto Langella declare no conflicts of interest. Cataldo Patruno received grants and personal fees from AbbVie, Almirall, Amgen, Eli Lilly, Galderma, La Roche-Posay, Leo Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi. Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung bioepis and Sanofi. Veronica Ottobrino is employed at Almirall S.p.A. Lorenzo Giovanni Mantovani has received grants and personal fees from Bayer AG, Boehringer Ingelheim, Pfizer and Daiichi-Sankyo. Paolo Angelo Cortesi has received a research grant from Baxalta, now part of Shire, and speaking honoraria from Pfizer and Roche.
: This article is based on mathematical modelling with inputs informed by previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
